Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

in Cinryze sales volume and increased selling, general and administrative expense

The change between our GAAP net income of $125.6 million for the year ended December 31, 2010 from GAAP net loss of $11.1 million in the same period of 2009 was primarily the result of our increased net sales in 2010 and the goodwill impairment of $65.1 million in 2009. The change in GAAP net income in the three months ended December 31, 2010 compared to 2009 was driven primarily by the increase in product sales.

Operating HighlightsCinryze net sales during the three and twelve months ended December 31, 2010 were $52.5 million and $176.8 million, respectively, a 46 percent and 82 percent increase over the respective periods in 2009 due to an increase in the number of patients receiving Cinryze. Vancocin net sales during the three and twelve months ended December 31, 2010 were $67.8 million and $259.6 million, respectively, or a 31 percent and 22 percent increase over the respective period in 2009 primarily due to net realized price growth during 2010, offset by lower sales volumes.

Cost of sales increased over the three and twelve month periods in the prior year by $6.0 million and $21.1 million, respectively, due to increased Cinryze volume partially offset by the impact of the step-up of inventory on 2009 cost of sales related to the acquisition of Lev.  As part of our October 2008 purchase of Lev, we acquired Cinryze inventory which was recorded at fair value in purchase accounting.  This fair value of inventory increased cost of sales for Cinryze during the year ended December 31, 2009 by $6.9 million.Research and development costs decreased $12.5 million during 2010 from 2009 primarily as a result of the winding down our stem cell and liver transplant studies in 2009 in our maribavir program. Selling, general and administrative expenses increased $6.3 million during 2010 compared to 2009.  The increase was driven by expenses related to
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), a ... announced that the company's YouTube channel on SEO ... on YouTube. The company uses YouTube as a way ... training for small businesses with much success. , "I ... helpful for their SEO strategies", explained Jason McDonald, director ...
(Date:5/17/2013)... news release is available in German . ... too well: with the naked eye, you can see which ... in the blur of branches through the telephoto lens for ... for researchers who are looking to study proteins, the active ... ETH Zurich,s Institute for Molecular Systems Biology, and her colleagues ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, ... based therapeutic agents and,Dalton Medicinal Chemistry, have ... therapeutics. Dalton Medicinal Chemistry will utilize ... novel classes of compounds against selected,RiboSwitch targets. ...
... Patients suffering from a range of debilitating illnesses, such as ... and ataxia stand to benefit from a new laboratory, established, ... China at the,forefront of the global race to engineer and reprogram ... ...
... Equity Research, Inc.,(Scimitar) issues a review of Neurobiological ... Viprinex(TM) Mission by a,Successful $60m Offering; Mountains Do ... website: http://www.scimitarequity.com . Neurobiological Technologies, Inc. ... of acquiring and developing central nervous system,related drug ...
Cached Biology Technology:BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology 2Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 2Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 3Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 4Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc. 2
(Date:5/16/2013)... scientist has discovered an ancient extinct creature with ,scissor ... in honour of his favourite movie star. , ... deppi (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ... actor Johnny Depp for his starring role as Edward ... Edward, an unfinished creation, who has scissors for hands. ...
(Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
(Date:5/16/2013)... -- The consultancy Frost & Sullivan presented ... Germany,s largest biometrics manufacturer, DERMALOG Identification ... DERMALOG has been honored yesterday night by Frost ... category Global Biometrics and Border Control  Customer Value Enhancement ... Control System . One of the decisive factors in ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4
... Development, Dr. Mary Ellen Perry and colleagues validate the ... therapies. , The p53 tumor suppressor plays a critical ... to activate p53 in order to curb tumor formation. ... an attractive target to modulate p53 activity in cells. ...
... Prostaglandins ?the fat-derived compounds linked to pain, inflammation, ... to their extensive catalog. , A new study ... the intricate cell movements during early embryonic development ... might influence human development and the spread of ...
... With an equal rate of incidence and mortality-the number of ... die from it-Glioblastoma Multiforme (GBM) is a brain cancer death ... with GBM annually in the U.S., half will die within ... only treatments that stretch survival limits are exceptionally invasive surgeries ...
Cached Biology News:Study fishes out new role for prostaglandins 2Study fishes out new role for prostaglandins 3Radiotherapy advance points way to noninvasive brain cancer treatment 2Radiotherapy advance points way to noninvasive brain cancer treatment 3
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting ... native protein. It reacts with free MMP-2 ... antibody buffered aqueous glycerol solution ... pH 7.4, containing 50% glycerol and 15 ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: